Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/28/2008 First Published: 4/1/1999


1.		Phase III Randomized Study of Dexamethasone Versus Prednisolone During Induction Therapy and Prolonged Versus Conventional Duration Asparaginase During Consolidation and Late Intensification Therapy in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 18				Other				EORTC-58951 NCT00003728

Last Modified: 2/12/2008 First Published: 11/1/2000


2.		Phase III Randomized Study of Induction and Maintenance Chemotherapy Regimens With Different Doses and Schedules of Methotrexate From the Berlin-Frankfurt-Munster-K2 Protocol With or Without Vinblastine in Children With Anaplastic Large Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 22				Other				FRE-IGR-ALCL99 EU-20031, NHL2000/06, NCT00006455

Last Modified: 12/11/2006 First Published: 5/23/2006


3.		Phase III Study of Induction and Maintenance Therapy Comprising Etoposide, Dexamethasone, and Cyclosporine Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Inherited or Severe and Persistent Secondary Hemophagocytic Lymphohistiocytosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				Under 18				Other				CCLG-LCH-2006-02 EU-20619, UKCCSG-HLH-2004, EUDRACT-2005-002187-28, NCT00334672

Last Modified: 1/13/2009 First Published: 9/23/2006


4.		Phase III Randomized Study of Low-Dose Versus High-Dose Vincristine and Combination Chemotherapy in Pediatric Patients With Intermediate-Risk Relapsed B-Precursor Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to under 30				NCI				COG-AALL0433 AALL0433, NCT00381680

Last Modified: 12/9/2008 First Published: 11/13/2006


5.		Phase III Randomized Study of Pegasparaginase Verus E. coli Asparaginase With Combination Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to 17				NCI				DFCI-05001 NCT00400946

Last Modified: 10/30/2008 First Published: 7/14/2006


6.		Phase I/II Pilot Study of Ifosfamide, Carboplatin, Etoposide, and Monoclonal Antibody SGN-30 in Pediatric Patients With CD30-Positive Recurrent Anaplastic Large Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				1 to 21				NCI				COG-ANHL06P1 ANHL06P1, NCT00354107

Last Modified: 1/1/2009 First Published: 3/24/2003


7.		Phase II Pilot Study of Rituximab Added to the Induction and Consolidation Phases and Rasburicase Added to the Reduction Phase in Children With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Treated With LMB/FAB Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				1 to 29				NCI				COG-ANHL01P1 NCT00057811, ANHL01P1

Last Modified: 1/13/2009 First Published: 11/22/2004


8.		Phase II Pilot Study of Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (Part A closed to accrual as of 10/30/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				2 to 31				NCI				COG-ADVL04P2 ADVL04P2, NCT00098839

Last Modified: 3/10/2008 First Published: 8/19/2005


9.		Phase II Study of Dose-Intensified Induction Therapy Comprising Cyclophosphamide, Vincristine, Prednisone, and Rituximab Followed by Consolidation Therapy Comprising Rituximab and High-Dose Cyclophosphamide in Adult Patients With Newly Diagnosed Burkitt or Atypical Burkitt Lymphoma or Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				30 and over				NCI				JHOC-J0409 JHOC-04-05-13-01, NCT00133991


10.		Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				15 to 24				Other				JALSG ALL202-U NCT00131053

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute